Cargando…

Filtering Inequality: Screening and Knowledge in Senegal’s Topography of Hepatitis B Care

Only a fraction of the estimated tenth or so of Senegalese who are chronically infected with hepatitis B virus (HBV) have been diagnosed. Of these, few have been assessed for their risk of progressing to potentially fatal liver disease (indicating need for treatment), and fewer still are taking anti...

Descripción completa

Detalles Bibliográficos
Autor principal: Tousignant, Noemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072661/
https://www.ncbi.nlm.nih.gov/pubmed/33912027
http://dx.doi.org/10.3389/fphar.2020.561428
_version_ 1783683958455664640
author Tousignant, Noemi
author_facet Tousignant, Noemi
author_sort Tousignant, Noemi
collection PubMed
description Only a fraction of the estimated tenth or so of Senegalese who are chronically infected with hepatitis B virus (HBV) have been diagnosed. Of these, few have been assessed for their risk of progressing to potentially fatal liver disease (indicating need for treatment), and fewer still are taking antiviral drugs. A massive gap between those needing and getting treatment is widely acknowledged among experts. But given that HBV and its biomedical treatment options are largely invisible in bodies, health data, care practices, public messaging, or mass media, how can we observe, ethnographically, the effects of constraints on and inequalities in treatment? What are the stakes of access to drugs, when this access is not being sought out, claimed, or enacted? This article tackles these questions by examining how HBV is being enacted in Senegal, but not necessarily in relation to antiviral treatment. I first describe the emergence, over the past decade and a half, of an exclusionary topography of HBV diagnosis and treatment. I introduce the notion of “filtration” to describe the effects of this topography on the formation of potential “subjects of access.” The diagnostic therapies and expertise required to determine need for treatment are expensive, urban, and largely privatized. Moreover, knowledge about HBV and its possibilities of care circulates in narrow and sparsely distributed channels. Only a tiny minority of persons are effectively “filtered into” care, while issues of access remain largely outside of public debate. I then move onto small-scale efforts, led by rural primary health workers and community associations, to raise awareness of and expand screening for HBV. Those driving information and screening either do not reveal that effective drugs exist or locate these beyond the reach of most of their audiences or patients. Why then do they do it? I examine the logics and effects of their work to identify the forms of inclusion, care, efficacy, and explanation these open up. At the same time, I seek to discern the indirect effects of unequal access to knowledge and resources in the ambivalence, uncertainties, and contradictions that pervade these efforts to inform, diagnose, and advise.
format Online
Article
Text
id pubmed-8072661
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80726612021-04-27 Filtering Inequality: Screening and Knowledge in Senegal’s Topography of Hepatitis B Care Tousignant, Noemi Front Pharmacol Pharmacology Only a fraction of the estimated tenth or so of Senegalese who are chronically infected with hepatitis B virus (HBV) have been diagnosed. Of these, few have been assessed for their risk of progressing to potentially fatal liver disease (indicating need for treatment), and fewer still are taking antiviral drugs. A massive gap between those needing and getting treatment is widely acknowledged among experts. But given that HBV and its biomedical treatment options are largely invisible in bodies, health data, care practices, public messaging, or mass media, how can we observe, ethnographically, the effects of constraints on and inequalities in treatment? What are the stakes of access to drugs, when this access is not being sought out, claimed, or enacted? This article tackles these questions by examining how HBV is being enacted in Senegal, but not necessarily in relation to antiviral treatment. I first describe the emergence, over the past decade and a half, of an exclusionary topography of HBV diagnosis and treatment. I introduce the notion of “filtration” to describe the effects of this topography on the formation of potential “subjects of access.” The diagnostic therapies and expertise required to determine need for treatment are expensive, urban, and largely privatized. Moreover, knowledge about HBV and its possibilities of care circulates in narrow and sparsely distributed channels. Only a tiny minority of persons are effectively “filtered into” care, while issues of access remain largely outside of public debate. I then move onto small-scale efforts, led by rural primary health workers and community associations, to raise awareness of and expand screening for HBV. Those driving information and screening either do not reveal that effective drugs exist or locate these beyond the reach of most of their audiences or patients. Why then do they do it? I examine the logics and effects of their work to identify the forms of inclusion, care, efficacy, and explanation these open up. At the same time, I seek to discern the indirect effects of unequal access to knowledge and resources in the ambivalence, uncertainties, and contradictions that pervade these efforts to inform, diagnose, and advise. Frontiers Media S.A. 2021-04-12 /pmc/articles/PMC8072661/ /pubmed/33912027 http://dx.doi.org/10.3389/fphar.2020.561428 Text en Copyright © 2021 Tousignant. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tousignant, Noemi
Filtering Inequality: Screening and Knowledge in Senegal’s Topography of Hepatitis B Care
title Filtering Inequality: Screening and Knowledge in Senegal’s Topography of Hepatitis B Care
title_full Filtering Inequality: Screening and Knowledge in Senegal’s Topography of Hepatitis B Care
title_fullStr Filtering Inequality: Screening and Knowledge in Senegal’s Topography of Hepatitis B Care
title_full_unstemmed Filtering Inequality: Screening and Knowledge in Senegal’s Topography of Hepatitis B Care
title_short Filtering Inequality: Screening and Knowledge in Senegal’s Topography of Hepatitis B Care
title_sort filtering inequality: screening and knowledge in senegal’s topography of hepatitis b care
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072661/
https://www.ncbi.nlm.nih.gov/pubmed/33912027
http://dx.doi.org/10.3389/fphar.2020.561428
work_keys_str_mv AT tousignantnoemi filteringinequalityscreeningandknowledgeinsenegalstopographyofhepatitisbcare